Rational Targeting of Prostate Cancer

Presenter: Dr. Mike Cox
Original Date: Tuesday, February 14, 2017

Description:
Dr. Cox will provide an overview of:
  • Prostate biology/physiology and an update on prostate cancer epidemiology in Canada.
  • How prostate cancer management has changed since 2010.
  • Emerging concepts of precision oncology and how they are being applied effectively to men with prostate cancer today and in the near future.
  • Recent research being performed on targeting a subtype of prostate cancer that carry TMPRSS2-ERG rearrangements. 

Dr. Mike Cox's Biography:

Dr. Cox is a molecular and cellular biologist who earned his PhD in Biochemistry from the University of North Carolina for studies on how cancer-causing genes normally function to control nerve growth and differentiation.  He began his work on cell signaling networks in cancer as a Research Associate at the University of Virginia.  He has established a research program in Vancouver dedicated to understanding how prostate cancer, the most frequently diagnosed male malignancy, initiates and progresses and to finding ways of halting advanced disease progression. 
 
Dr. Cox’s research is currently funded by operating grants from the Terry Fox Foundation, Canadian Institute for Health Research and Prostate Cancer Canada. His work focuses on early genetic changes in prostate cells, how resulting tumor cells respond to growth factors in the presence or absence of testosterone and how these cellular changes allow prostate tumor cells to utilize these growth factors to aid development of testosterone independence. 
 
In conjunction with colleagues at the Vancouver Prostate Centre and University of British Columbia and industrial partnerships, he is developing combinatorial drug strategies that decrease the responsiveness of tumor cells to growth factors and has shown that prostate cancer cells treated in this way are more sensitive to testosterone deprivation or treatment with other chemotherapies. These are first steps in developing effective treatments for patients with advanced prostate cancer.

About Expert Angle

Expert Angle is designed to expand our reach and address the many varied and complex questions that come with a prostate cancer diagnosis. These webinars will address topics important to men with prostate cancer along different points of the cancer care continuum and those within their circle of care as well as the general public and representatives from the clinical community.
 
The meetings are hosted using interactive on-line technology and feature leading experts in prostate cancer - making them accessible to anyone, regardless of their location, within Canada. The platform allows PCC to communicate directly with individuals in a variety of settings (i.e. in their homes, support group meetings, community centres) and geographic locations (i.e. urban, rural and remote locations) as well as measure engagement.   

View more Expert Angle webinars.

   

Donate Now!




Subscribe to our free monthly e-newsletter!

* indicates required

 





 
PCC Spotlight
Rock the Road Raffle returns with its most valuable car to date

A 2018 Acura NSX to be prized by Prostate Cancer Canada and TADA at the AutoShow  
More

Prostate Cancer Canada and the Movember Foundation Announce $4M in Research Grants

Toronto, October 23, 2018 – Prostate Cancer Canada and the Movember Foundation today announced $4 million in funding to three Canadian researchers to predict how well prostate cancer will respond to treatment, based on men’s biological markers, specifically in their tumour cells and blood – opening a path to more personalized care with fewer side effects and a better chance of survival.
More

Gay and bisexual men living with prostate cancer focus of research

Vancouver, September 25, 2018 – Research funded by Prostate Cancer Canada is preparing the way to improve quality of life for men-who-have-sex-with-men (MSM)1 in the LGBTQ2+ community.
More


Click here for news archive